Intraoperative Folate Targeted Fluorescence in Renal Cell Carcinoma

NACompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

December 29, 2015

Primary Completion Date

March 20, 2018

Study Completion Date

April 2, 2019

Conditions
Renal Cell Carcinoma
Interventions
DRUG

OTL38

OTL38 is a folate analog conjugated with a fluorescent dye that emits light in the near infrared spectrum. This longer wavelength allows for deeper penetration of the fluorescent light through tissues with the potential to better image tumors beneath adipose tissue or deeper into organ parenchyma.

DEVICE

Intraoperative fluorescence imaging system

Trial Locations (2)

46202

Indiana University Health Hospital, Indianapolis

Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis

All Listed Sponsors
lead

Chandru Sundaram

OTHER

NCT02645409 - Intraoperative Folate Targeted Fluorescence in Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter